Pancreatic Cancer Research

ResearcherPurdue University West LafayetteActive in the last 2 years

Matthew J. Flick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5034-3162; OpenAlex author ID A5016211446; NIH RePORTER profile ID 2315255. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 2)
Trials
0
Grants
3
Labs led
2
Collaborators
23
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 2 grants · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers, 1 grant

Papers 8

  1. Depletion of Fibrinogen Suppresses Growth of Primary Tumors and Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.09.024↗
  2. Extravascular coagulation stabilizes pro-fibrotic stromal states via tumor-intrinsic PAR1 signaling in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.06.25.734662↗
  3. Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models. Co-author DOI 10.1126/sciadv.adq0513↗
  4. Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression. Last author DOI 10.1002/1878-0261.13552↗
  5. Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment. Co-author DOI 10.1111/jth.15115↗
  6. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Co-author DOI 10.1182/bloodadvances.2020003149↗
  7. Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms22105138↗
  8. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion. Last author DOI 10.1158/0008-5472.can-18-3206↗

Grants 3

  1. Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor Microenvironment U01CA274304↗
  2. Thrombin-dependent mechanisms of pancreatic ductal adenocarcinoma disease R01CA211098↗
  3. Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis U01HL143403↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Melissa L. Fishel · 3 shared papers, 2 shared grants, 2022–2026 · strength 2.10
  2. Bumsoo Han · 1 shared paper, 2 shared grants, 2022–2026 · strength 1.70
  3. Stephen F Konieczny · 2 shared papers, 1 shared grant, 2019–2022 · strength 0.87
  4. Alisa S. Wolberg · 2 shared papers, 1 shared grant, 2022–2026 · strength 0.85
  5. Sae Rome Choi · 2 shared papers, 2026 · strength 0.47
  6. Nayela N. Chowdhury · 2 shared papers, 2024–2026 · strength 0.40
  7. Yi Yang · 3 shared papers, 2019–2024 · strength 0.39
  8. Aditi Kothari · 1 shared paper, 2021 · strength 0.28
  9. Hye‐ran Moon · 1 shared paper, 2026 · strength 0.25
  10. Claudius H. Conrad · 1 shared paper, 2026 · strength 0.25
  11. Nigel Mackman · 2 shared papers, 2021 · strength 0.24
  12. Virginia Metrangolo · 1 shared paper, 2025 · strength 0.24
  13. Lars Henning Engelholm · 1 shared paper, 2025 · strength 0.24
  14. Silpa Gampala · 1 shared paper, 2026 · strength 0.22
  15. Wei Ping Jia · 1 shared paper, 2026 · strength 0.22
  16. Patrick G. Schweickert · 2 shared papers, 2019–2021 · strength 0.21
  17. Fenil Shah · 1 shared paper, 2024 · strength 0.18
  18. Emily White · 1 shared paper, 2021 · strength 0.12
  19. Florian Moik · 1 shared paper, 2021 · strength 0.12
  20. Yohei Hisada · 1 shared paper, 2021 · strength 0.12
  21. Tomohiro Kawano · 1 shared paper, 2021 · strength 0.12
  22. Ingrid Pabinger · 1 shared paper, 2021 · strength 0.12
  23. Cihan Ay · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.